Timothy M. Block
36Patents
9h-index
40Co-inventors
75Inventor score
Filing activity: Oct 6, 1993 → Apr 20, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8097728B2 | Iminosugar compounds with antiflavirus activity | Human Necessities | 40 | Active |
| US8609668B2 | Substituted triazolo[1,5-A]pyrimidines as antiviral agents | Human Necessities | 39 | Active |
| US9623071B2 | Modulation of hepatitis B virus CCCDNA transcription | Chemistry; Metallurgy | 27 | Active |
| US6689759B1 | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy | Human Necessities | 18 | Expired |
| US6465487B1 | Inhibition of membrane-associated viral replication | Emerging Cross-Sectional Technologies | 14 | Expired |
| US9399619B2 | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection | Human Necessities | 12 | Active |
| US7816560B1 | Long chain n-alkyl compounds and oxa-derivatives thereof | Emerging Cross-Sectional Technologies | 10 | Expired |
| US7776550B2 | Diagnosis of liver pathology through assessment of protein glycosylation | Physics | 10 | Expired |
| US9089515B2 | Long chain N-alkyl compounds and oxa-derivatives thereof | Emerging Cross-Sectional Technologies | 9 | Active |
| US6809083B1 | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | Human Necessities | 9 | Expired |
| US8183000B2 | Diagnosis of liver pathology through assesment of protein glycosylation | Physics | 6 | Active |
| US9642830B2 | Use of sting agonists to treat hepatitis B virus infection | Physics | 5 | Active |
| US5532124A | Genetically engineered bacteria to identify and produce medically important agents | Emerging Cross-Sectional Technologies | 4 | Expired |
| US10045961B2 | Use of sting agonists to treat chronic hepatitis B virus infection | Physics | 3 | Active |
| US6037351A | Method of inhibiting hepatitis B virus | Human Necessities | 2 | Expired |
| US7612093B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | Human Necessities | 2 | Active |
| US8921381B2 | Inhibitors of secretion of hepatitis B virus antigens | Human Necessities | 1 | Active |
| US6355248B1 | Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent | Emerging Cross-Sectional Technologies | 1 | Expired |
| US9110078B2 | Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation | Physics | 1 | Active |
| US10143720B2 | Modulation of hepatitis B virus cccDNA transcription | Chemistry; Metallurgy | 0 | Active |
| US10421723B2 | 2,3-diacylated, 2- and 3-mono-acylated alkylated imino sugars exhibiting glucosidase inhibition and their method of use | Chemistry; Metallurgy | 0 | Active |
| US10180436B2 | Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation | Physics | 0 | Active |
| US9126937B2 | Alkylated imino sugars exhibiting glucosidase inhibition and their method of use | Chemistry; Metallurgy | 0 | Active |
| US9657013B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | Chemistry; Metallurgy | 0 | Active |
| US8193328B2 | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.